Marcelo Bigal, Ventus Therapeutics CEO
February 9, 2022 10:34 AM ESTUpdated 02:49 PM
Financing

Up­dat­ed: RA Cap­i­tal and Soft­Bank head up the lat­est nine-fig­ure crossover, this time for Ven­tus. Will an IPO soon fol­low?

Max Gelman

Senior Editor

A biotech pre­vi­ous­ly backed by Ver­sant and GV is un­veil­ing its newest fi­nanc­ing round, com­ing with a slate of blue-chip in­vestors that could sig­nal an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times